NIH Scientists Create Pain Reliever Without Addiction Risk

Scientists at the National Institutes of Health have discovered something that pain medicine experts once thought impossible: an opioid that works powerfully without the deadly risks.

The new drug, called DFNZ, delivers strong pain relief without slowing breathing or creating the conditions that lead to addiction. In laboratory studies, it performed unlike any opioid scientists have seen before.

"Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose," said Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse. "Developing a highly effective pain medication without these drawbacks would have enormous public health benefits."

The discovery started when researchers revisited nitazenes, a group of synthetic opioids abandoned in the 1950s because they were too powerful. The team wondered if they could redesign these compounds to keep their pain-fighting abilities while removing the dangers.

What they found exceeded expectations. The compound DFNZ relieves pain for at least two hours without suppressing breathing at therapeutic doses. When tested repeatedly, it didn't create tolerance or the severe withdrawal symptoms typical of opioids.

The team tested whether the drug had addictive potential by training rats to press a lever for doses. The animals did seek out DFNZ initially, showing some rewarding effects. However, when researchers replaced the drug with saline, the rats quickly stopped seeking it, unlike what happens with heroin, morphine, or fentanyl.

Why This Inspires

The reason DFNZ works differently comes down to brain chemistry. It increases dopamine slowly and steadily rather than creating the sharp spikes that form powerful drug cravings. Without those dramatic surges, the brain doesn't form the intense associations that drive addiction and relapse.

"DFNZ has an unprecedented pharmacology for an opioid," said Dr. Michael Michaelides, the study's senior author. "Its capacity to be administered at therapeutic doses without producing respiratory depression is very important."

The findings challenge decades of belief that highly active opioid drugs cannot be safe. Scientists now think DFNZ could work not just for pain relief but also as a treatment for opioid use disorder itself, offering advantages over current therapies that still carry breathing risks.

The research team plans to continue preclinical work toward eventual human trials. They believe the drug could help surgical patients, cancer patients, and people with chronic pain who need reliable relief without fear.

For the hundreds of thousands of families touched by the opioid crisis, this research represents genuine hope: powerful pain relief that doesn't steal lives in return.